A phase I clinical trial has been undertaken to study the therapeutic effect of KRAS G12D siRNA delivered by mesenchymal stromal cell-derived exosomes in pancreatic cancer patients (NCT03608631). Here, KRAS is linked to familial pancreatic carcinoma.